Union Budget 2026-27 introduces Biopharma SHAKTI with ₹10,000 crore outlay to boost biologics, biosimilars, healthcare skills and medical hubs.
Read Morebiosimilars
Alkem launches Pertuza biosimilar in India for HER2-positive breast cancer treatment
Alkem launches Pertuza biosimilar in India, offering affordable HER2-positive breast cancer treatment and strengthening its oncology portfolio.
Read More
UDENYCA Acquired by Intas Pharmaceuticals and Accord BioPharma in Biosimilar Expansion
UDENYCA, a biosimilar to Amgen’s Neulasta, is indicated to reduce the risk of infection due to febrile neutropenia in patients with non-myeloid malignancies undergoing myelosuppressive chemotherapy.
Read More